PATIENT PORTAL | HOME | CONTACT US | LOGIN
 
Print
Email to a Friend

Understanding My Results

Treatment plans are most effective when based on an individual’s specific type of cancer and test results.  At our institution, we combine many factors in addition to a patient's Gleason score and PSA to design and implement the best treatment available.

For the lay person, this information can be overwhelming.  We provide a comprehensive overview for you here to help educate you about the tools available in the treatment of prostate.  An understanding of these tools may be helpful in making your decision about treatment options.

  1. Gleason Score
    A widely used method for classifying the cellular differentiation of cancerous tissue. The less the cancerous cells appear like normal cells, the more malignant the cancer. Two grades of 1-5, identifying the two most common degrees of differentiation found in the examined tissue sample, are added together to produce the Gleason score, which can range from 2 to 10. High numbers indicate greater differentiation and more aggressive cancer. The grading system is named after its originator, Donald Gleason, MD.
     
  2. PSA (Prostate Specific Antigen)
    A blood test that measures a substance manufactured almost exclusively by prostate gland cells. It is produced by both normal and cancerous cells. An elevated reading indicates an abnormal condition of the prostate gland, either benign or malignant. It is presently the most sensitive tumor marker for the identification and monitoring of prostate cancer.
    (read more)
     
  3. Other testing useful in understanding your cancer
    PAP (Prostatic Acid Phosphatase) – An enzyme produced by the prostate that is elevated (3.0 or higher) in many patients when prostate cancer has spread beyond the prostate.
    (read more)

  4. Beyond the Prostate
    USPIO is an exciting new development in nanotechnology which is unique to Dattoli Cancer Center.  Collaborating with Dr. Charles Myers (AIDP), Dr. Stephen Bravo (SLI) and Dr. Jelle Barentsz (U Nijmegan), our research is demonstrating the equivalence to Combidex® imaging using Ferumoxytol.  Meanwhile, using advanced fusion technologies, Ferumoxytol imaging from Sand Lake Imaging (SLI) can be directly transported into the software at DCC.  This is the ultimate staging tool for patients having high risk prostate cancer and we believe will help eradicate cancers which would otherwise remain unbeknownst to the treating Radiation and Medical Oncologist.  This is perhaps the most exciting research being performed at DCC and we believe will result in a paradigm shift in how more advanced prostate cancer is approached.
    (read more)


Dattoli Cancer Center

2803 Fruitville Road : Sarasota, FL 34237
1-877-DATTOLI (328-8654)
941.957.1221 : 941.957.0038 (fax)